Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers

Overview

Journal J Clin Med

Specialty General Medicine

Date 2019 Jul 21

PMID 31323990

Citations 25

Authors

Luigi Pasini

Paola Ulivi

Affiliations

Soon will be listed here.

Abstract

The use of targeted agents and immunotherapy for the treatment of advanced non-small-cell lung cancer (NSCLC) has made it mandatory to characterize tumor tissue for patient selection. Moreover, the development of agents that are active against specific resistance mechanisms arising during treatment make it equally important to characterize the tumor tissue at progression by performing tissue re-biopsy. Given that tumor tissue is not always available for molecular characterization due to the paucity of diagnostic specimens or problems relating to the carrying out of invasive procedures, the use of liquid biopsy represents a valid approach to overcoming these difficulties. The most common material used for liquid biopsy in this setting is plasma-derived cell free DNA (cfDNA), which originates from cells undergoing apoptosis or necrosis. However, other sources of tumor material can be considered, such as extracellular vesicle (EV)-derived nucleic acids, which are actively secreted from living cells and closely correspond to tumor dynamics. In this review, we discuss the role of liquid biopsy in the therapeutic management of NSCLC with particular regard to targeted therapy and immunotherapy, and analyze the pros and cons of the different types of samples used in this context.

Citing Articles

Current Issues of Next-Generation Sequencing-Based Circulating Tumor DNA Analysis in Colorectal Cancer.

Rathnasamy N, Lavingia V, Aggarwal S, Talwar V, Shukla P, Rohtagi N South Asian J Cancer. 2025; 13(4):241-245.

PMID: 40060356 PMC: 11888803. DOI: 10.1055/s-0044-1801755.

Liquid biopsy in gastric cancer: A snapshot of the current state of the art.

Gasparello J, Ceccon C, Angerilli V, Comunello T, Sabbadin M, DAlmeida Costa F J Liq Biopsy. 2025; 7:100288.

PMID: 40027230 PMC: 11863821. DOI: 10.1016/j.jlb.2025.100288.

Mutational spectrum of breast cancer by shallow whole-genome sequencing of cfDNA and tumor gene panel analysis.

Ambriz-Barrera F, Rojas-Jimenez E, Diaz-Velasquez C, De-La-Cruz-Montoya A, Martinez-Gregorio H, Ruiz-De-La-Cruz M PLoS One. 2024; 19(9):e0308176.

PMID: 39264897 PMC: 11392417. DOI: 10.1371/journal.pone.0308176.

Diagnostic accuracy of ESR1 mutation detection by cell-free DNA in breast cancer: a systematic review and meta-analysis of diagnostic test accuracy.

Raei M, Heydari K, Tabarestani M, Razavi A, Mirshafiei F, Esmaeily F BMC Cancer. 2024; 24(1):908.

PMID: 39069608 PMC: 11283726. DOI: 10.1186/s12885-024-12674-z.

Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.

Peters S, Gadgeel S, Mok T, Nadal E, Kilickap S, Swalduz A Nat Med. 2024; 30(7):1923-1932.

PMID: 38898120 PMC: 11271410. DOI: 10.1038/s41591-024-03008-4.

References

Kwok H, Ning Z, Chong P, Wan T, Ng M, Ho G . Transfer of Extracellular Vesicle-Associated-RNAs Induces Drug Resistance in ALK-Translocated Lung Adenocarcinoma. Cancers (Basel). 2019; 11(1). PMC: 6356387. DOI: 10.3390/cancers11010104. View

Douillard J, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G . Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014; 9(9):1345-53. PMC: 4224589. DOI: 10.1097/JTO.0000000000000263. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Nishino M, Suda K, Kobayashi Y, Ohara S, Fujino T, Koga T . Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. Lung Cancer. 2018; 126:149-155. DOI: 10.1016/j.lungcan.2018.10.026. View

El Andaloussi S, Mager I, Breakefield X, Wood M . Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12(5):347-57. DOI: 10.1038/nrd3978. View

Ulivi P . Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?. Int J Mol Sci. 2016; 17(7). PMC: 4964555. DOI: 10.3390/ijms17071186. View

Jasinski-Bergner S, Mandelboim O, Seliger B . The role of microRNAs in the control of innate immune response in cancer. J Natl Cancer Inst. 2014; 106(10). DOI: 10.1093/jnci/dju257. View

Shaw A, Engelman J . ALK in lung cancer: past, present, and future. J Clin Oncol. 2013; 31(8):1105-11. PMC: 4209068. DOI: 10.1200/JCO.2012.44.5353. View

Li C, Iida M, Dunn E, Ghia A, Wheeler D . Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene. 2009; 28(43):3801-13. PMC: 2900381. DOI: 10.1038/onc.2009.234. View

10.

Uchibori K, Inase N, Nishio M, Fujita N, Katayama R . Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment. J Thorac Oncol. 2018; 13(7):915-925. DOI: 10.1016/j.jtho.2018.04.005. View

11.

Jia Y, Li X, Zhao C, Jiang T, Zhao S, Zhang L . Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer. Lung Cancer. 2018; 125:22-28. DOI: 10.1016/j.lungcan.2018.08.025. View

12.

Tong B, Xu Y, Zhao J, Chen M, Zhong W, Xing J . Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer. Thorac Cancer. 2018; 9(5):640-645. PMC: 5928386. DOI: 10.1111/1759-7714.12631. View

13.

Robbins P, Morelli A . Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014; 14(3):195-208. PMC: 4350779. DOI: 10.1038/nri3622. View

14.

Fidler M, Frankenberger C, Seto R, Lobato G, Fhied C, Sayidine S . Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy. Oncotarget. 2017; 8(35):58108-58121. PMC: 5601637. DOI: 10.18632/oncotarget.17510. View

15.

Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L . Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007; 67(7):2912-5. DOI: 10.1158/0008-5472.CAN-07-0520. View

16.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

17.

Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J . The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clin Cancer Res. 2016; 22(22):5527-5538. DOI: 10.1158/1078-0432.CCR-16-0569. View

18.

Schwarzenbach H, Nishida N, Calin G, Pantel K . Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014; 11(3):145-56. DOI: 10.1038/nrclinonc.2014.5. View

19.

Katayama R, Lovly C, Shaw A . Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res. 2015; 21(10):2227-35. PMC: 4435823. DOI: 10.1158/1078-0432.CCR-14-2791. View

20.

Shen J, Liu Z, Todd N, Zhang H, Liao J, Yu L . Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 2011; 11:374. PMC: 3175224. DOI: 10.1186/1471-2407-11-374. View